MedTrace Logo

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

NCT05600036 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2025-06-18

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

ESK-001

Oral tablet

DRUG

Placebo

Oral tablet

Sponsors & Collaborators

  • Alumis Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2023-06-29
Completion
2023-07-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05600036 on ClinicalTrials.gov